Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan in HFrEF with Pulmonary Hypertension
NCT05487261Phase 4Unknown
- Start
- Dec 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), pulmonary hypertension (PH). Status: unknown.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT05487261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487261.